Changes in microRNA expression in the MG-63 osteosarcoma cell line compared with osteoblasts

Oncology Letters

Volumn 4, Issue 5, 2012, Pages 1037-1042

  Hu, Hao ^a   Zhang, Yi ^a   Cai, Xian Hua ^a   Huang, Ji Feng ^a   Cai, Lin ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Aberrant expression; Function; MicroRNA; Osteoblast; Osteosarcoma; Target gene

Indexed keywords

BRCA1 PROTEIN; COLLAGENASE 3; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; FIBROBLAST GROWTH FACTOR RECEPTOR 3; INTERSTITIAL COLLAGENASE; KRUPPEL LIKE FACTOR 6; MACROPHAGE ELASTASE; MAMMALIAN TARGET OF RAPAMYCIN; MATRIX METALLOPROTEINASE 14; MICRORNA; MICRORNA 143; MICRORNA 145; MICRORNA 148A; MICRORNA 181A; MICRORNA 195; MICRORNA 335; MICRORNA 539; MICRORNA 9; MICRORNA 99; MITOGEN ACTIVATED PROTEIN KINASE 7; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 4; PROTEIN BCL 2; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; SMAD3 PROTEIN; TRANSCRIPTION FACTOR CDX2; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; VASCULOTROPIN A;

ARTICLE; BIOINFORMATICS; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; ONCOGENE H RAS; OSTEOBLAST; OSTEOSARCOMA; OSTEOSARCOMA CELL; PREDICTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

EID: 84866056904     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.866     Document Type: Article

References (65)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
2. Messerschmitt PJ, Rettew AN, Brookover RE, Garcia RM, Getty PJ and Greenfield EM: Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro. Clin Orthop Relat Res 466: 2168-2175, 2008.
3. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A and PicciP: Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 106: 1154-1161, 2006.
4. Longhi A, Errani C, De Paolis M, Mercuri M and Bacci G: Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 32: 423-436, 2006.
5. Zhang Y, Wei RX, Zhu XB, Cai L, Jin W and Hu H: Tanshinone IIA induces apoptosis and inhibits the proliferation, migration and invasion of the osteosarcoma MG-63 cell line in vitro. Anticancer Drugs 23: 212-219, 2012.
6. Kobayashi E, Hornicek FJ and Duan Z: MicroRNA involvement in osteosarcoma. Sarcoma 2012: 359739, 2012.
7. Lulla RR, Costa FF, Bischof JM, et al: Identification of differentially expressed microRNAs in osteosarcoma. Sarcoma 2011: 732690, 2011.
8. Lujambio A and Lowe SW: The microcosmos of cancer. Nature 482: 347-355, 2012.
9. Rottiers V and Näär AM: MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol 13: 239-250, 2012.
10. Zhang W and Dolan ME: The emerging role of microRNAs in drug responses. Curr Opin Mol Ther 12: 695-702, 2010.
11. Wang L, Oberg AL, Asmann YW, et al: Genome-wide transcriptional profiling reveals microRNA-correlated genes and biological processes in human lymphoblastoid cell lines. PLoS One 11: e5878, 2009.
12. Zhao H, Shen J, Medico L, Wang D, Ambrosone CB and Liu S: A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One 5: e13735, 2010.
13. Guo L, Liu Y, Bai Y, Sun Y, Xiao F and Guo Y: Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. Eur J Cancer 46: 1692-1702, 2010.
14. Vergoulis T, Vlachos IS, Alexiou P, et al: TarBase 6.0: capturing the exponential growth of miRNA targets with experimental support. Nucleic Acids Res 40 (Database issue):D222-D229, 2012.
15. Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP and Zhuang SM: MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology 50: 113-121, 2009.
16. Ye W, Lv Q, Wong CK, et al: The effect of central loops in miRNA:MRE duplexes on the efficiency of miRNA-mediated gene regulation. PLoS One 3: e1719, 2008.
17. Liu L, Chen L, Xu Y, Li R and Du X: microRNA-195 promotes apoptosis and suppresses tumorigenicity of human colorectal cancer cells. Biochem Biophys Res Commun 400: 236-240, 2010.
18. Murakami Y, Yasuda T, Saigo K, et al: Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25: 2537-2345, 2006.
19. Lin Y, Wu J, Chen H, et al: Cyclin-dependent kinase 4 is a novel target in micoRNA-195-mediated cell cycle arrest in bladder cancer cells. FEBS Lett 586: 442-447, 2012.
20. Oneyama C, Ikeda J, Okuzaki D, et al: MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways Oncogene 30: 3489-3501, 2011.
21. Hafner M, Landthaler M, Burger L, et al: Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell 141: 129-141, 2010.
22. Doghman M, El Wakil A, Cardinaud B, et al: Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer Res 70: 4666-4675, 2010.
23. Guo LM, Pu Y, Han Z, et al: MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF-kappaB1. FEBS J 276: 5537-5546, 2009.
24. Ma L, Young J, Prabhala H, et al: miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 12: 247-256, 2010.
25. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP and Bartel DP: MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 27: 91-105, 2007.
26. Liffers ST, Munding JB, Vogt M, et al: MicroRNA-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting CDC25B. Lab Invest 91: 1472-1479, 2011.
27. Zheng B, Liang L, Wang C, et al: MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clin Cancer Res 17: 7574-7583, 2011.
28. Cuesta R, Martínez-Sánchez A and Gebauer F: miR-181a regulates cap-dependent translation of p27(kip1) mRNA in myeloid cells. Mol Cell Biol 29: 2841-2851, 2009.
29. Zhu W, Shan X, Wang T, Shu Y and Liu P: miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 127: 2520-2529, 2010.
30. Shin KH, Bae SD, Hong HS, Kim RH, Kang MK and Park NH: miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras. Biochem Biophys Res Commun 404: 896-902, 2011.
31. Ji J, Yamashita T, Budhu A, et al: Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 50: 472-480, 2009.
32. Zhang X, Nie Y, Du Y, Cao J, Shen B and Li Y: MicroRNA-181a promotes gastric cancer by negatively regulating tumor suppressor KLF6. Tumour Biol 33: 921-928, 2012.
33. Chiyomaru T, Enokida H, Tatarano S, et al: miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer 102: 883-891, 2010.
34. Kano M, Seki N, Kikkawa N, et al: miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 127: 2804-2814, 2010.
35. Zhang J, Sun Q, Zhang Z, Ge S, Han ZG and Chen WT: Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop. Oncogene 28: 1038-1046, 2012.
36. Akao Y, Nakagawa Y and Naoe T: MicroRNA-143 and-145 in colon cancer. DNA Cell Biol 26: 311-320, 2007.
37. Osaki M, Takeshita F, Sugimoto Y, et al: MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Mol Ther 19: 1123-1130, 2011.
38. Borralho PM, Kren BT, Castro RE, da Silva IB, Steer CJ and Rodrigues CM: MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells. FEBS J 276: 6689-6700, 2009.
39. Chen X, Guo X, Zhang H, et al: Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 28: 1385-1392, 2009.
40. Heyn H, Engelmann M, Schreek S, et al: MicroRNA miR-335 is crucial for the BRCA1 regulatory cascade in breast cancer development. Int J Cancer 129: 2797-2806, 2011.
41. Tavazoie SF, Alarcón C, Oskarsson T, et al: Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451: 147-152, 2008.
42. Lee YN, Brandal S, Noel P, et al: KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation. Blood 117: 3629-3640, 2011.
43. Patnaik SK, Kannisto E and Yendamuri S: Overexpression of microRNA miR-30a or miR-191 in A549 lung cancer or BEAS-2B normal lung cell lines does not alter phenotype. PLoS One 5: e9219, 2010.
44. Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM and MatzukMM: High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci USA 109: 3921-3926, 2012.
45. Puerta-Gil P, García-Baquero R, Jia AY, et al: miR-143, miR-222 and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am J Pathol 180: 1808-1815, 2012.
46. Cortez MA, Welsh JW and Calin GA: Circulating microRNAs as noninvasive biomarkers in breast cancer. Recent Results Cancer Res 195: 151-161, 2012.
47. Mendell JT and Olson EN: MicroRNAs in stress signaling and human disease. Cell 148: 1172-1187, 2012.
48. Varkonyi-Gasic E and Hellens RP: Quantitative stem-loop RT-PCR for detection of microRNAs. Methods Mol Biol 744: 145-157, 2011.
49. Saito T and Saetrom P: MicroRNAs-targeting and target prediction. N Biotechnol 27: 243-249, 2010.
50. Peter ME: Targeting of mRNAs by multiple miRNAs: the next step. Oncogene 29: 2161-2164, 2010.
51. Wu S, Huang S, Ding J, et al: Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3' untranslated region. Oncogene 29: 2302-2308, 2010.
52. Thomson DW, Bracken CP and Goodall GJ: Experimental strategies for microRNA target identification. Nucleic Acids Res 39: 6845-6853, 2011.
53. Farazi TA, Spitzer JI, Morozov P and Tuschl T: miRNAs in human cancer. J Pathol 223: 102-115, 2011.
54. Shenouda SK and Alahari SK: MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev 28: 369-378, 2009.
55. Zhang H, Cai X, Wang Y, Tang H, Tong D and Ji F: microRNA-143, down-regulated in osteosarcoma, promotes apoptosis and suppresses tumorigenicity by targeting Bcl-2. Oncol Rep 24: 1363-1369, 2010.
56. Fan L, Wu Q, Xing X, Wei Y and Shao Z: MicroRNA-145 targets vascular endothelial growth factor and inhibits invasion and metastasis of osteosarcoma cells. Acta Biochim Biophys Sin (Shanghai) 44: 407-414, 2012.
57. Li D, Liu X, Lin L, et al: MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem 286: 36677-36685, 2011.
58. Sun D, Lee YS, Malhotra A, et al: miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. Cancer Res 71: 1313-1324, 2011.
59. Özata DM, Caramuta S, Velázquez-Fernández D, et al: The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocr Relat Cancer 18: 643-655, 2011.
60. Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, MüllerSC and Ellinger J: Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 77: 1265. e9-16, 2011.
61. Cho WC: Epigenetic alteration of microRNAs in feces of colorectal cancer and its clinical significance. Expert Rev Mol Diagn 11: 691-694, 2011.
62. Jones KB, Salah Z, Del Mare S, et al: miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res 72: 1865-1877, 2012.
63. White NM, Bao TT, Grigull J, et al: miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. J Urol 186: 1077-1083, 2011.
64. Vickers MM, Bar J, Gorn-Hondermann I, et al: Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease. Clin Exp Metastasis 29: 123-132, 2012.
65. Shu M, Zhou Y, Zhu W, et al: MicroRNA 335 is required for differentiation of malignant glioma cells induced by activation of cAMP/protein kinase A pathway. Mol Pharmacol 81: 292-298, 2012.